Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
02-05 February, 2026
Not Confirmed
Not Confirmed
03-05 February, 2026
Paris Packaging WeekParis Packaging Week
Not Confirmed
Not Confirmed
05-06 February, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
SCOPE Summit
Not Confirmed
Contact SupplierSCOPE Summit
Industry Trade Show
Not Confirmed
02-05 February, 2026
Industry Trade Show
Not Confirmed
03-05 February, 2026
Paris Packaging WeekParis Packaging Week
Industry Trade Show
Not Confirmed
05-06 February, 2026
Digital content
NEWS #PharmaBuzz
19 Dec 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/12/19/3208453/0/en/Cue-Biopharma-Announces-Pricing-of-10-Million-Public-Offering.html
18 Dec 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/12/18/3208167/0/en/Cue-Biopharma-Announces-Proposed-Public-Offering.html
13 Nov 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20251113268855/en/Singapore-based-ImmunoScape-Pioneers-Next-Generation-Cell-Therapy-for-Solid-Tumors-Announces-Key-Licensing-Deal-New-Board-and-SAB-Appointments
12 Nov 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/11/12/3186774/0/en/Cue-Biopharma-Reports-Third-Quarter-2025-Financial-Results-and-Recent-Business-Highlights.html
06 Nov 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/11/06/3182503/0/en/Cue-Biopharma-and-ImmunoScape-Announce-Strategic-Collaboration-to-Develop-Breakthrough-Cell-Therapy-Approach-for-Solid-Tumors.html
29 Sep 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/09/29/3157785/0/en/Cue-Biopharma-Announces-Strategic-Transition-in-Leadership-to-Further-Enable-Next-Stage-of-Growth-with-Disruptive-Autoimmune-Therapeutic-Candidates.html
Drugs in Development
Details:
The proceeds from the offering will be used to fund the clinical development of CUE-401, a small molecule product targeting IL-2R/TGF-beta in the treatment of autoimmune diseases.
Lead Product(s): CUE-401
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Miscellaneous
Sponsor: H.C. Wainwright & Co
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 19, 2025
Lead Product(s) : CUE-401
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : H.C. Wainwright & Co
Deal Size : $10.0 million
Deal Type : Public Offering
Cue Biopharma Prices $10M Public Offering
Details : The proceeds from the offering will be used to fund the clinical development of CUE-401, a small molecule product targeting IL-2R/TGF-beta in the treatment of autoimmune diseases.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
December 19, 2025
Details:
The proceeds from the offering will be used to fund the clinical development of CUE-401, a small molecule product targeting IL-2R/TGF-beta in autoimmune disease.
Lead Product(s): CUE-401
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Miscellaneous
Sponsor: H.C. Wainwright & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering December 18, 2025
Lead Product(s) : CUE-401
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : H.C. Wainwright & Co
Deal Size : Undisclosed
Deal Type : Public Offering
Cue Biopharma Announces Public Offering
Details : The proceeds from the offering will be used to fund the clinical development of CUE-401, a small molecule product targeting IL-2R/TGF-beta in autoimmune disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
December 18, 2025
Details:
Through the licensing deal for CUE-101, targeting HPV E7, the agreement aims to advance treatment options for solid tumor cancers.
Lead Product(s): CUE-101,Pembrolizumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Protein
Sponsor: ImmunoScape
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 13, 2025
Lead Product(s) : CUE-101,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : ImmunoScape
Deal Size : Undisclosed
Deal Type : Licensing Agreement
ImmunoScape pioneers cell therapy for solid tumors; announces licensing deal, new appointments.
Details : Through the licensing deal for CUE-101, targeting HPV E7, the agreement aims to advance treatment options for solid tumor cancers.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Undisclosed
November 13, 2025
Details:
The collaboration aims to advance solid tumor treatment with the CUE-100 series targeting IL-2R, TCR, and KRAS.
Lead Product(s): CUE-100 series
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Protein
Sponsor: ImmunoScape
Deal Size: $30.0 million Upfront Cash: $15.0 million
Deal Type: Collaboration November 06, 2025
Lead Product(s) : CUE-100 series
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : ImmunoScape
Deal Size : $30.0 million
Deal Type : Collaboration
Cue Biopharma, ImmunoScape Partner for Solid Tumor Cell Therapy
Details : The collaboration aims to advance solid tumor treatment with the CUE-100 series targeting IL-2R, TCR, and KRAS.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : $15.0 million
November 06, 2025
Details:
The collaboration aims to accelerate the development of CUE-501, a bispecific designed to direct selective memory T cells to target and deplete B cells. It is being evaluated for autoimmune disease.
Lead Product(s): CUE-501
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Antibody, Unconjugated
Sponsor: Boehringer Ingelheim GmbH
Deal Size: $357.0 million Upfront Cash: $12.0 million
Deal Type: Collaboration April 14, 2025
Lead Product(s) : CUE-501
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Boehringer Ingelheim GmbH
Deal Size : $357.0 million
Deal Type : Collaboration
Boehringer and Cue Biopharma Partner for Autoimmune and Inflammatory Disease Therapies
Details : The collaboration aims to accelerate the development of CUE-501, a bispecific designed to direct selective memory T cells to target and deplete B cells. It is being evaluated for autoimmune disease.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : $12.0 million
April 14, 2025
Details:
CUE-102 is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Glioblastoma.
Lead Product(s): CUE-102
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Protein
Sponsor: David Reardon
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 09, 2025
CUE-102 in Recurrent Glioblastoma
Details : CUE-102 is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Glioblastoma.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
April 09, 2025
Details:
The proceeds will advance the clinical development of company's autoimmune programs, including CUE-401, a bispecific fusion protein designed to induce and expand regulatory T cells, and CUE-501.
Lead Product(s): CUE-401
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Protein
Sponsor: Oppenheimer & Co. Inc.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering September 26, 2024
Lead Product(s) : CUE-401
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Oppenheimer & Co. Inc.
Deal Size : Undisclosed
Deal Type : Public Offering
Cue Biopharma Announces Proposed Public Offering
Details : The proceeds will advance the clinical development of company's autoimmune programs, including CUE-401, a bispecific fusion protein designed to induce and expand regulatory T cells, and CUE-501.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Undisclosed
September 26, 2024
Details:
The proceeds will advance the clinical development of company's autoimmune programs, including CUE-401, a bispecific fusion protein designed to induce and expand regulatory T cells, and CUE-501.
Lead Product(s): CUE-401
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Protein
Sponsor: Oppenheimer & Co. Inc.
Deal Size: $12.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 26, 2024
Lead Product(s) : CUE-401
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Oppenheimer & Co. Inc.
Deal Size : $12.0 million
Deal Type : Public Offering
Cue Biopharma Announces Pricing of $12.0 Million Public Offering
Details : The proceeds will advance the clinical development of company's autoimmune programs, including CUE-401, a bispecific fusion protein designed to induce and expand regulatory T cells, and CUE-501.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Undisclosed
September 26, 2024
Details:
CUE-101 is a novel fusion protein that incorporates HLA-A*0201 allele (the MHC portion) bound to an epitope from the HPV 16 E7 protein, which is investigated in combination with pembrolizumab for the treatment head and neck squamous.
Lead Product(s): CUE-101,Pembrolizumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Protein
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 26, 2023
Lead Product(s) : CUE-101,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CUE-101 is a novel fusion protein that incorporates HLA-A*0201 allele (the MHC portion) bound to an epitope from the HPV 16 E7 protein, which is investigated in combination with pembrolizumab for the treatment head and neck squamous.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
September 26, 2023
Details:
Under the terms of the agreement, Cue Biopharma will be responsible for the research and development of CUE-401, a bispecific protein designed to induce and expand regulatory T cells (Tregs) for the treatment of autoimmune and inflammatory diseases.
Lead Product(s): CUE-401
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Protein
Sponsor: Ono Pharmaceutical
Deal Size: $220.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration February 22, 2023
Lead Product(s) : CUE-401
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Ono Pharmaceutical
Deal Size : $220.0 million
Deal Type : Collaboration
Details : Under the terms of the agreement, Cue Biopharma will be responsible for the research and development of CUE-401, a bispecific protein designed to induce and expand regulatory T cells (Tregs) for the treatment of autoimmune and inflammatory diseases.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Undisclosed
February 22, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
Share 
